C A Siegel

Summary

Affiliation: Dartmouth-Hitchcock Medical Center
Country: USA

Publications

  1. pmc What options do we have for induction therapy for Crohn's disease?
    Corey A Siegel
    Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Dig Dis 28:543-7. 2010
  2. pmc Predicting Response to Anti-TNF Agents for the Treatment of Crohn's Disease
    Corey A Siegel
    Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
    Therap Adv Gastroenterol 2:245-51. 2009
  3. doi Translating improved quality of care into an improved quality of life for patients with inflammatory bowel disease
    Corey A Siegel
    Section of Gastroenterology and Hepatology, Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Clin Gastroenterol Hepatol 11:908-12. 2013
  4. ncbi Foam preparations for the treatment of ulcerative colitis
    Burr J Loew
    Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Curr Drug Deliv 9:338-44. 2012
  5. doi Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options
    Corey A Siegel
    Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Gut 61:459-65. 2012
  6. pmc Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease
    Corey A Siegel
    Dartmouth Hitchcock Inflammatory Bowel Disease Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    Inflamm Bowel Dis 17:30-8. 2011
  7. pmc When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations
    Corey A Siegel
    Dartmouth Hitchcock Inflammatory Bowel Disease Center, Lebanon, New Hampshire, USA
    Inflamm Bowel Dis 16:1658-62. 2010
  8. doi Review article: explaining risks of inflammatory bowel disease therapy to patients
    C A Siegel
    Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Aliment Pharmacol Ther 33:23-32. 2011
  9. pmc Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis
    Corey A Siegel
    Dartmouth Hitchcock IBD Center and Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, Massachusetts, USA
    Clin Gastroenterol Hepatol 7:874-81. 2009
  10. pmc Making therapeutic decisions in inflammatory bowel disease: the role of patients
    Corey A Siegel
    Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03755, USA
    Curr Opin Gastroenterol 25:334-8. 2009

Detail Information

Publications22

  1. pmc What options do we have for induction therapy for Crohn's disease?
    Corey A Siegel
    Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Dig Dis 28:543-7. 2010
    ..The art of treating the IBD patient is in understanding the options and being able to apply an individualized regimen based upon unique patient and disease factors...
  2. pmc Predicting Response to Anti-TNF Agents for the Treatment of Crohn's Disease
    Corey A Siegel
    Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
    Therap Adv Gastroenterol 2:245-51. 2009
    ..However, further work in this area along with multivariate clinical prediction modeling may soon allow us to deliver 'personalized medicine' by predicting individualized treatment response in patients with Crohn's disease...
  3. doi Translating improved quality of care into an improved quality of life for patients with inflammatory bowel disease
    Corey A Siegel
    Section of Gastroenterology and Hepatology, Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Clin Gastroenterol Hepatol 11:908-12. 2013
    ..All of this work is intended to make quality improvement programs both feasible and useful, with the ultimate goal of improving quality of life for our patients. ..
  4. ncbi Foam preparations for the treatment of ulcerative colitis
    Burr J Loew
    Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Curr Drug Deliv 9:338-44. 2012
    ..This review focuses on clinical trials assessing efficacy, tolerability, and patient preferences for these agents as well as describing the currently available rectal foam products...
  5. doi Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options
    Corey A Siegel
    Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Gut 61:459-65. 2012
    ..The overall goal is to involve patients in decisions so that they are educated about their options, confident in the plan, adherent to chosen therapy and ultimately have a better quality of life...
  6. pmc Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease
    Corey A Siegel
    Dartmouth Hitchcock Inflammatory Bowel Disease Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    Inflamm Bowel Dis 17:30-8. 2011
    ..The aim of this project was to develop a tool to graphically display the predicted risks of CD and expected benefits of therapy...
  7. pmc When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations
    Corey A Siegel
    Dartmouth Hitchcock Inflammatory Bowel Disease Center, Lebanon, New Hampshire, USA
    Inflamm Bowel Dis 16:1658-62. 2010
    ..The objective was to learn if UC patients' perceptions of their colon cancer risk and if their preferences for elective colectomy match with physicians' recommendations if dysplasia was found...
  8. doi Review article: explaining risks of inflammatory bowel disease therapy to patients
    C A Siegel
    Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Aliment Pharmacol Ther 33:23-32. 2011
    ....
  9. pmc Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis
    Corey A Siegel
    Dartmouth Hitchcock IBD Center and Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, Massachusetts, USA
    Clin Gastroenterol Hepatol 7:874-81. 2009
    ....
  10. pmc Making therapeutic decisions in inflammatory bowel disease: the role of patients
    Corey A Siegel
    Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03755, USA
    Curr Opin Gastroenterol 25:334-8. 2009
    ..This review aims to describe what we know about patients' perceptions of risks and benefits of treatment, how much risk IBD patients are willing to accept, and to introduce ideas to facilitate better patient communication...
  11. ncbi Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease
    Corey A Siegel
    Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    Inflamm Bowel Dis 14:1-6. 2008
    ..The aim of this study was to determine patients' and parents' perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease (IBD)...
  12. pmc Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model
    Corey A Siegel
    Dartmouth Hitchcock Inflammatory Bowel Disease Center, Lebanon, New Hampshire, USA
    Clin Gastroenterol Hepatol 10:46-51. 2012
    ..We sought to define the frequency at which a rare adverse event would have to occur for the risks of combination therapy to outweigh the benefits of treatment...
  13. pmc Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy
    Corey A Siegel
    Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Inflamm Bowel Dis 16:2168-72. 2010
    ..By more clearly communicating with patients, we can ensure that they are making informed medical decisions that fit with their personal preferences for treatment...
  14. ncbi Risks and benefits of infliximab for the treatment of Crohn's disease
    Corey A Siegel
    Section of Gastroenterology and Hepatology, Inflammatory Bowel Disease Center, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, New Hampshire, USA
    Clin Gastroenterol Hepatol 4:1017-24; quiz 976. 2006
    ..The purpose of this study was to analyze the risks and benefits of infliximab for the treatment of Crohn's disease with the goal of providing data to aid both physicians and patients in the process of making a decision about treatment...
  15. doi Modelling dysplasia detection in ulcerative colitis: clinical implications of surveillance intensity
    D Awais
    Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    Gut 58:1498-503. 2009
    ..Endoscopic surveillance of chronic colitis uses random biopsies to find dysplastic fields. Enhanced endoscopic methods are more sensitive for dysplasia detection, but their specificity for colorectal cancer risk is unknown...
  16. ncbi As if mothers don't have enough to worry about
    Corey A Siegel
    Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    Inflamm Bowel Dis 12:146-7. 2006
  17. doi Isolated asymptomatic ileitis does not progress to overt Crohn disease on long-term follow-up despite features of chronicity in ileal biopsies
    Elizabeth L Courville
    Department of Pathology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Am J Surg Pathol 33:1341-7. 2009
    ..001). Isolated ileitis detected in asymptomatic patients undergoing polyp screening or surveillance does not evolve into CD on follow-up, despite endoscopic and histologic overlap with findings typically seen in CD...
  18. ncbi Risk factors for colorectal cancer in Crohn's colitis: a case-control study
    Corey A Siegel
    Section of Gastroenterology and Hepatology, Inflammatory Bowel Disease Center, Dartmouth Medical School, Lebanon, NH, and Gastrointestinal Unit, MGH Crohn s and Colitis Center, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Inflamm Bowel Dis 12:491-6. 2006
    ..Few data exist regarding exposures associated with colorectal cancer (CRC) in patients with Crohn's colitis. The aim of this study was to identify exposures that alter the risk of CRC in patients with Crohn's colitis...
  19. pmc A new tool to measure the burden of Crohn's disease and its treatment: do patient and physician perceptions match?
    Allison R Wilcox
    Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    Inflamm Bowel Dis 16:645-50. 2010
    ..Our aim was to develop and test a simple tool to measure the burden of Crohn's disease (CD) and its treatment and to compare how patients and their physicians perceive the impact of CD on HRQOL...
  20. ncbi Embracing the internet for progress in shared decision-making
    Corey A Siegel
    Inflamm Bowel Dis 13:1579-80. 2007
  21. ncbi Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy
    F Reed Johnson
    Research Triangle Institute RTI International, Research Triangle Park, North Carolina, USA
    Gastroenterology 133:769-79. 2007
    ..The aim of this study is to estimate the willingness of Crohn's disease (CD) patients to accept life-threatening adverse event risks in exchange for CD symptom relief...
  22. ncbi Possible association between isotretinoin and inflammatory bowel disease
    Deepa Reddy
    Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Am J Gastroenterol 101:1569-73. 2006
    ..Our aim was to perform a systematic examination of reports of IBD associated with isotretinoin use...